NCT03607188View on ClinicalTrials.gov

Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 18, 2018

Primary Completion Date

October 17, 2022

Study Completion Date

October 17, 2022

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Alkotinib

Alkotinib 200mg QD、 Alkotinib 300mg QD、 Alkotinib 400mg QD、 Alkotinib 500mg QD、 Alkotinib 600mg QD

Trial Locations (1)

Unknown

Shanghai Eastern Hospital, Shanghai

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT03607188 - Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter